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Abstract
Sex determining region Y-box 2 (Sox2) is a transcription factor essential for
maintaining self-renewal and pluripotency of undifferentiated embryonic stem
cells. Sox2 is involved in multiple processes of cancer cells, however, regulation
of Sox2 expression and the consequences of that regulation in cancer remains
elusive. Previously, we demonstrated that BMP9/GDF2 is significantly reduced in
expression in ovarian cancer (OVCA) cells, methylated in patient tumors and,
promoted anoikis resistance in both breast and OVCA cell lines. In an attempt to
identify genes downstream of BMP9 that may provide anoikis resistance,
transcriptomics was performed leading to the identification of Sox2, a
developmental gene, as being significantly down regulated in response to BMP9.
I find that Sox2 expression is broadly suppressed by BMP members including
BMP2, BMP4 and BMP9 both in a time and dose dependent manner. To identify
the specific ALK receptors utilized for Sox2 repression by BMPs, we used inhibitors
to the ALK receptors and find specifically that ALK2 and ALK3 are receptors
utilized by BMPs for Sox2 regulation. We also examined if Sox2 repression occurs
via SMAD activation and find that SMAD1 activation is required for BMP-mediated
Sox2 downregulation. This was validated via sh-RNA based approaches. Data
from Sox2 promoter reporter assay suggests the involvement of the Sox2 promoter
as the regulatory region involved in BMP-mediated downregulation, which was
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confirmed by expressing Sox2 from a heterologous CMV promoter which failed to
be repressed by BMP. Furthermore, we find that de novo protein and RNA
synthesis is required for BMP-mediated Sox2 repression as determined using
cycloheximide and actinomycin D respectively. My findings indicate that BMP is a
mediator of Sox2 downregulation in cancer, occurring via SMAD1-dependent
mechanisms.
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Chapter 1
Introduction
Ovarian cancer is the seventh most common cancer worldwide and the
most lethal of all gynecological cancers1. Epithelial ovarian cancer comprises 90%
of all ovarian cancers. Most patients with this disease have advanced stage
disease at the time of diagnosis as a result of the disease already metastasizing
to other regions in the body. Metastasis from epithelial ovarian cancer can occur
via

the

transcoelomic,

hematogeneous, or lymphatic

route.

Of

these,

transcoelomic metastasis is the most common, and is responsible for the greatest
morbidity and mortality in women with this disease2. This is denoted with the ability
of the ovarian carcinoma to seed the peritoneal cavity with nests of tumor cells and
the formation of ascites. The motility and invasive behavior of ovarian carcinoma
cells are regulated by a repertoire of signaling pathways3.
Bone Morphogenetic Proteins (BMPs) comprise the largest subgroup of the
transforming growth factor-β (TGF-β) superfamily of multifunctional cytokines that
play important roles in the majority of morphogenetic processes during
development4. BMPs control a diverse range of cellular responses such as
differentiation, proliferation, apoptosis etc5. Upon ligand (BMP) binding to its type
I receptor (ALK1, 2, 3 and 6), the type I receptor recruits the type II receptor
(BMPRII) which has constitutively active receptor kinase activity that transphosph-
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orylates and activates the kinase activity of the type I receptor. Once active, the
ALK’s phosphorylate the intracellular effector proteins, Smad1/5/8 which complex
with the common partner, Smad4, to accumulate in the nucleus where it further
associates with coactivators or corepressors to regulate gene expression6. Various
BMP members have been shown to reduce or enhance tumorigenesis and
metastasis. Thus, implicating BMPs as having a dual role both in cancer
progression and suppression7.
Sex-determining region Y- box 2 (Sox2) is a transcription factor that interact
with DNA through a highly conserved HMG domain8, and has a transactivation
domain at its C terminus9. Sox2 belongs to group B of the Sox family, encoded by
a single-exon gene on chromosome 3q26.3-q272010. The HMG-domain box
ensures precise DNA recognition and highly specific DNA binding. Sox proteins
can bind to ATTGTT or related sequence motifs through their HMG domain, which
consists of three α helices11,12. Sox2 was initially found to maintain the embryonic
stem cell pluripotency13. More recently, Sox2 is being shown to be involved in a
series of malignancies. Numerous studies have shown that Sox2 promotes cell
proliferation, migration, invasion and tumor metastasis in several cancers14,15.
Moreover, high expression levels of Sox2 correlate with tumor progression or poor
prognosis of multiple cancers. Ye. F., et al. found that Sox2 is significantly
overexpressed in OVCA tissues compared with normal ovary tissues16. These
findings suggest that Sox2 might act as a tumor promoting gene in OVCA.
However, how Sox2 expression is regulated, the functional roles and precise
mechanisms of action of Sox2 in OVCA remains elusive.
2

In a previous study, our lab found that BMP9, a member of the BMP family,
is significantly reduced in expression in several cancer cell lines, especially ovarian
cancer, and in patient tumors via epigenetic silencing of the BMP9 promoter by
methylation17. Therefore, identification of downstream gene targets in which BMPs
regulate and understanding the molecular mechanisms of BMP regulations on
downstream genes will be crucial in providing a better insight into combating this
disease. In this study, we find that Sox2 is a downstream repressed target of BMP.
We show that BMP-mediated Sox2 downregulation in ovarian cancer cell lines PA1
and OVCAR3 occurs via SMAD1-dependent mechanism, as well as, identified
ALK2 as the Type I receptor utilized in Sox2 repression by BMPs. Furthermore,
we find that BMP-mediated Sox2 downregulation requires new RNA and protein
synthesis.
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Chapter 2
Results
Characterization of the effect of BMP on Sox2 expression in Ovarian Cancer
We previously demonstrated that BMP9/GDF2 is significantly reduced in
expression in OVCA cells and showed that BMP9 significantly enhances anoikis
sensitivity in ovarian cancer17. In an attempt to identify genes downstream of BMP9
that may provide anoikis resistance, we performed microarray analysis and find
Sox2 to be significantly downregulated in response to BMP9 with about 11-fold
decrease in gene expression (Figure 2.1A). To validate the microarray data, we
performed quantitative-Polymerase Chain Reaction (qPCR) and confirmed Sox2
downregulation in response to BMP9 at the mRNA level (Figure 2.1B). Next, we
screened a panel of OVCA cells to identify cancer model systems for Sox2
expression, and find PA1 and OVCAR3 to have the most robust Sox2 expression
at the protein and mRNA level as indicated by the western blotting and qPCR data,
while OVCA433 and OVCA420 have the least Sox2 expression in the panel
(Figure 2.1C). We examined the effect of the broader BMP family members on
Sox2 expression and find that Sox2 expression is broadly suppressed by BMP
members including BMP2, BMP4 and BMP9 both at the protein and mRNA level
in PA1 and OVCAR3 (Figure 2.1D-E) (data not shown for BMP4). Furthermore, we
performed immunofluorescence to observe changes in Sox2 protein localization in
response to BMP2 and BMP9. We find that Sox2 is tightly localized in the nucleus
4

and its levels in the nucleus gets significantly reduced in response to BMP2 and
BMP9 (Data not shown). This finding corroborates the western blotting data, thus,
confirms that BMP2 and BMP9 downregulates Sox2 protein expression.
To determine the dose dependency of BMP2 and BMP9 on Sox2
expression, we performed a dose course analysis of BMP2 and BMP9 on Sox2
expression and find 10 nM to be an optimum dose to mediate Sox2 downregulation
in response to BMP in PA1 and OVCAR3 (Figure 2.2C). To investigate the kinetics
of Sox2 downregulation in response to BMP at the protein and mRNA level, we
carried out a time-course analysis of Sox2 expression in response to BMP2 and
BMP9 in PA1 and OVCAR3. We find that downregulation of Sox2 expression in
response to BMP begins after 6 hours at the protein and mRNA levels. These
findings were validated in PA1 and OVCAR3 (Figure 2.2 A-B).
Role of ALK receptors in BMP-mediated Sox2 repression
To identify the specific ALK receptors involved in Sox2 repression by BMPs,
we carried out inhibition assay of the ALK receptors by treating with chemical
inhibitors which blocks the activity of the receptors in phosphorylating downstream
SMADs. First, we first confirmed SMAD1/5 and SMAD2/3 activation in response
to BMP2 and BMP9 by carrying out a time-course analysis of SMAD1/5
phosphorylation in PA1. Robust SMAD1/5 could be observed as early as
15minutes in response to treatment with BMP2 and BMP9, while, slight SMAD2/3
phosphorylation was observed (Figure 2.3). PA1 and OVCAR3 cells were
pretreated for 1 hr with Dorsomorphin (inhibitor of ALK 2, 3 and 6), SB431542
(inhibitor of ALK 4, 5 and 7), ML347 (inhibitor of ALK 1, 2) and LDN193189
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(inhibitor of ALK 2, 3), followed by treatment with BMP2 or BMP9 for 24 hr. We find
that dorsomorphin partially suppresses BMP-mediated Sox2 downregulation with
about 60% recovery in Sox2 expression both at the protein and mRNA level and
completely blocked BMP-induced SMAD1/5 activation in PA1 and OVCAR3.
SB431542 had no effect on BMP-mediated Sox2 downregulation in PA1 and
OVCAR3 and this rule out the involvement of ALK 4, 5 and 7 in BMP-mediated
Sox2

downregulation

(Figure

2.4A-B).

Interestingly,

ML347

significantly

suppressed BMP9-mediated Sox2 downregulation both at the protein and mRNA
level and completely blocked BMP9-induced SMAD1/5 activation in PA1 and
OVCAR3,

however,

only

partially

suppressed

BMP2-mediated

Sox2

downregulation with about 80% recovery in Sox2 expression and partially block
BMP2-induced SMAD1/5 activation in PA1 and OVCAR3. Finally, treatment with
LDN193189 fully suppressed both BMP2- and BMP9- mediated Sox2
downregulation with total recovery in Sox2 expression both at the protein and
mRNA level and completely blocked BMP-induced SMAD1/5 activation in PA1 and
OVCAR3 (Figure 2.4C-D). This data identifies ALK 2/3 as the ALK receptors
utilized in BMP-mediated Sox2 downregulation in OVCA, as well as suggests a
role for SMAD1 in Sox2 repression by BMPs.
BMP-mediated Sox2 downregulation is via SMAD1-dependent mechanisms
Recent studies showed that BMP members can activate both the canonical
SMAD1/5-dependent and SMAD-2/3 signaling pathways, therefore, we aimed to
identify the signaling machinery utilized for BMP-mediated Sox2 downregulation.
Data from the ALK inhibition studies above indicates that SMAD1 activation is
6

required for BMP-mediated Sox2 repression. Therefore, we confirmed this
involvement of SMAD1 by making independent knockdown of SMAD1 using
shRNA -based approach. We find that the effect of BMP on Sox2 expression was
significantly abrogated by shRNA to SMAD1 when compared to the control cells in
OVCAR3 (Figure 2.5A). These results confirm the requirement for SMAD1
activation in BMP-mediated Sox2 downregulation.
Furthermore, BMP9 and BMP10 form a subgroup within the BMP families
based on similarities in their primary amino acid sequences, as well as,
overlapping function in angiogenesis. BMP9 and especially BMP10 were reported
to utilize an endothelial specific ALK1 receptor which activates SMAD1/5. We
reported that unlike BMP9, BMP10 cannot activate SMAD1/5 in epithelial cells.
Thus, we further investigated this requirement for SMAD1/5 activation in BMPmediated Sox2 downregulation by examining the effect of BMP10 on Sox2
expression. We find that BMP10 cannot downregulate Sox2 expression in OVCA
epithelial cells (Figure 2.1F), thus, confirms our result states that SMAD1 activation
is required for Sox2 repression by BMPs.
Effect of non-SMAD pathways on BMP-mediated Sox2 downregulation
Research has shown that BMP can utilize SMAD and non-SMAD pathways
to mediate its downstream effects. Here, we investigated the involvement of the
non-canonical signaling pathway in Sox2 regulation by BMPs. This was done by
blocking the ‘committed’ intermediates of the non-SMAD pathway - MAP Kinase,
Wnt, Phosphoinositide 3-Kinase/FAK, Erk, YAP signaling pathways using the
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following inhibitors: U0126, IWP-4, PF431396, and Verteporfin respectively in
BMP-mediated Sox2 downregulation.
We find that treatment with UO126 had no effect on BMP-mediated Sox2
downregulation while treatment with IWP-4 slightly suppressed BMP-mediated
Sox2 downregulation (Figure 2.7 A-B). We found this interesting as recent studies
reports a crosstalk between BMP and wnt signaling pathway. We also showed that
5 µM IWP-4 was optimum to reduce pLRP6 (committed intermediate) levels to
basal level (Figure 2.7C). Despite reports of crosstalk between the PI3K pathway
and BMP, as well as, BMP and Yap pathway, our result indicates that these
pathways do not play a role in BMP-mediated Sox2 downregulation as treatment
with PF431396 (PI3K/FAK inhibitor) did not affect BMP-mediated Sox2
downregulation (Figure 2.8A). Interestingly, treatment with 10 nM verteporfin seem
to slightly suppress the effect of BMP on Sox2 expression, however, increasing
the dose of verteporfin to 20 nM showed more strongly that Yap pathway is not
involved in BMP-mediated Sox2 downregulation (Figure 2.8B).
Although, BMP has been reported to utilize some non-SMAD dependent
pathways to mediate its downstream effect, however, our data suggests that BMPmediated Sox2 downregulation occurs via SMAD1 dependent mechanism.
Nonetheless, the involvement of wnt signaling in BMP-mediated Sox2
downregulation seems very promising yet our data in Figure 2.9C shows that BMP
slightly activates LRP6 which is a co-receptor for wnt signaling.
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BMP reduces Sox2 promoter transcriptional activity
To determine whether Sox2 promoter is involved in BMP-mediated Sox2
downregulation, we performed luciferase reporter assay using a 1kb pGL3-Sox2
promoter construct in HEK293 cells. We find that BMP significantly reduces Sox2
transcriptional activity (Figure 2.6B). We confirmed the role of Sox2 promoter by
expressing Sox2 from a heterologous CMV promoter in SKOV3 cells, followed by
treatment with BMP. We find that cell line with the overexpression construct
(SKOV3-cmv-Sox2OE) resulted in no repression in Sox2 levels in response to
BMP, when compared to control cells (Figure 2.6A). This data confirms the
involvement of Sox2 promoter in BMP-mediated Sox2 downregulation.
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Figure 2.1 Characterization of the effect of BMP members on Sox2
expression in Ovarian Cancer. (A) Microarray analysis in PA1 cells identifying
Sox2 as one of the most repressed gene upon treatment with BMP9 and (B) qRTPCR validation of the microarray result, (C) (i) Western blot and (ii) qRT-PCR
screening for Sox2 expression in a panel of OVCA cells. (D-E) Western blot and
qRT-PCR of the effect of 10 nM BMP2 and BMP9 on Sox2 expression in PA1 and
OVCAR3 cells. Cells were treated for 24 hr in serum-free media (F) Effect of
broader BMP members on Sox2 protein expression in PA1. Cells were treated with
10 nM of the indicated BMP’s for 24 hr in serum-free media. All error bars represent
the mean ± SEM. ***p<0.001, **p<0.01, *p<0.05. Two-tailed t-tests was used to
test for significance.
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Figure 2.2 (Figure 2.1 continued). (A-B) Time course analysis of effect of 10 nM BMP2 and BMP9 on Sox2 expression
at the Protein and mRNA level in PA1 and OVCAR3, (C) Dose course of BMP2 and BMP9 on Sox2 expression in PA1 and
OVCAR3. All error bars represent the mean ± SEM. ***p<0.001, **p<0.01, *p<0.05. One way ANOVA, Bonferroni multiple
comparison test.

Figure 2.3 SMAD1/5 activation in response to BMP. Time course of Smad1/5
and Smad2/3 phosphorylation in PA1 cells in response to 10 nM BMP2 and
BMP9. Lysates were analyzed by immunoblotting with the indicated antibodies.
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Figure 2.4 Identification of ALK receptors utilized for Sox2 repression by BMP. Western blot and qPCR for (A) PA1
and (B) OVCAR3 cells pretreated with 5μM Dorsomorphin (ALK 2,3 and 6 inhibitor) and SB431542 (ALK4,5 and 7
inhibitor) for 1hr, followed by treatment with BMP2 and BMP9 for 24 hr (i-iv). Western blot and qPCR of (C) PA1 and (D)
OVCAR3 cells pretreated with 3μM ML347 (ALK 1,2 inhibitor) and 0.8μM LDN193189 (ALK 2,3 inhibitor) for 1hr, followed
by treatment with BMP2 and BMP9 for 24 hr. . All error bars represent the mean ± SEM. ***p<0.001, **p<0.01, *p<0.05.
One way ANOVA, Bonferroni multiple comparison test.

Figure 2.5. Role of SMAD1 and SMAD4 in BMP-mediated Sox2
downregulation. A) OVCAR3 cells transiently expressing shRNA to SMAD1
(shSMAD1) or Non-targeting control (NTC) in indicated cells for 72 hr. (i) qPCR
showing expression of SMAD1 to validate knockdown. Values are normalized to
their Non-targeting control. (ii) Western blot analysis of OVCAR3 cells expressing
shSMAD1 or NTC, treated with the indicated BMP for 24 hr. (iii) qPCR showing
relative expression of SMAD1 and (iv) Sox2 in shSMAD1- and NTC- OVCAR3
cells, followed by treatment with BMP for 24 hr. B) qPCR showing relative
expression of (i) SMAD4 and (ii) Sox2 in siSMAD4- and NTC- OVCAR3 cells,
followed by treatment with BMP for 24 hr. All error bars represent the mean ± SEM.
***p<0.001, **p<0.01, *p<0.05. One way ANOVA, Bonferroni multiple comparison
test.
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Figure 2.6. Role of Sox2’s promoter in mediating Sox2
downregulation by BMP. A) SKOV3 cells stably expressing Sox2
over-expression (Sox2OE) from a CMV promoter or control (CMV-ctrl)
vector, were treated with BMP for 24 hr. B) HEK293 cells were transfected
with 1kb pGL3-Sox2 promoter-reporter construct (500 ng). Luciferase
reporter activity in the absence or presence of BMP for 24 hr is presented.
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Figure 2.7 Supplementary figure 1. Western
blot of PA1 cells pretreated with 5µM U0126
and 5µM IWP-4 for 1 hr, followed by treatment
with BMP9 (A) and BMP2 (B) for 24h.
(C) Immunoblot of lysate for pLRP6 in response
to treatment with IWP-4.
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Figure 2.8 Supplementary figure 2. Western blot of
PA1 cells pretreated with (A) 5 µM PF431396 and
(B) Verteporfin (dose indicated) for 1 hr, followed by
treatment with BMP for 24 hr.
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Chapter 3
Discussion
BMP play pleiotropic roles during embryonic development depending on
their dose, duration of treatment and state of the cell. BMP has been reported to
play a dichotomous role in tumorigenesis where it could act as a tumor suppressor
or tumor promoter7. Here, we show for the first time a role for BMP in Sox2
regulation in OVCA. We showed that Sox2 repression is broadly mediated by
members of the BMP family - BMP2, BMP4 and BMP9 at the protein and mRNA
level in OVCA cells, both in a time and dose dependent manner in PA1 and
OVCAR3. BMP signaling has been known to occur via the canonical SMAD1/5
signaling pathway, however, recent studies revealed that some members of the
BMP family can activate both the canonical SMAD1/5 and non-canonical SMAD2/3
signaling pathway. We find BMP significantly activates Smad1/5 with limited
activation of Smad2/3 (Figure 2.3). Biochemical studies using inhibitors to the ALK
receptors identifies ALK2 and ALK3 receptors as the receptors utilized by BMP to
mediate Sox2 repression, evidenced as treatment with LDN193189 resulted in
total inhibition of Sox2 downregulation in response to BMP in PA1 and OVCAR3
cells (Figure 2.4). Furthermore, Sox2 regulation was found to be via SMAD1dependent mechanism using shRNA-based approaches. Knockdown of SMAD1
suppressed the effect of BMP on Sox2 expression in OVCAR3 cells (Figure 2.5).
In addition, BMP10, which we had previously reported as unable to activate
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SMAD1/5 in epithelial OVCA cells as BMP10 preferably binds to ALK1 receptor
(17),

had no effect on Sox2 expression (Figure 2.1F).BMP-mediated Sox2

downregulation was completely abrogated when cells were pretreated with CHX
followed by treatment with BMP (Figure 2.7A-B). Similarly, treatment with ActD
suppressed BMP-mediated Sox2 downregulation (Figure 2.7C). Therefore, these
results suggest that de novo protein and RNA synthesis is required for BMPmediated Sox2 downregulation.
Furthermore, we find that Sox2 promoter is a regulatory region involved in
BMP-mediated Sox2 downregulation from our readout of the luciferase promoterreporter assay. This was confirmed by the Sox2 overexpression study using a
heterologous promoter cmv to drive Sox2 expression. Treatment with BMP had no
effect on Sox2 expression in Skov3-cmv-Sox2, thus, confirming the involvement
of the promoter region in BMP-mediated Sox2 downregulation (Figure 2.6A).
Further studies about mechanism of interaction of SMAD1 with epigenetic
modifiers on the Sox2 promoter will be helpful in providing a better insight into the
dynamics of the mechanism of action of Smad1 in Sox2 regulation.
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Chapter 4
Materials and Methods
Cell Lines and Culture Conditions
Ovarian teratoma and epithelial carcinoma cell lines were obtained from
both Duke Gynecology/Oncology Bank (Durham, NC) and NIH. Authentication was
carried out at the University of Colorado (Denver, CO) sequencing facility.
Carcinoma cell lines PA1, OVCAR4, OVCAR5, 41M, IGROV, HEY, A2780, SKOV3 and PE01 were cultured in RPMI-1640 (ATCC® 30-2001TM) containing Lglutamine, 10% FBS and 100U of penicillin-streptomycin while OVCAR3,
OVCAR420, OVCAR433 were cultured same as above except without penicillinstreptomycin. HEK293 cells were grown in complete DMEM supplemented with Lglutamine, 10% fetal bovine serum (FBS) and 100 U of penicillin-streptomycin. Cell
from patient sample EOC08, EOC10, EOC14, EOC15, EOC17 were obtained from
Pennsylvania State Hershey medical center (Hershey, PA). All cell lines were
maintained at 37oC in a humidified incubator at 5% CO2, routinely checked for
mycoplasma 3 times a year (MycoAlert PLUS mycoplasma detection kit, Lonza,
Basel, Switzerland) and experiments conducted within 3-6 passages depending
on the cell line.
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Antibodies and Reagents
Antibodies phospho-SMAD1/5 (#9516), phospho-SMAD2/3 (#8828S),
SMAD1 (#6944S), SMAD2 (#5678S), SMAD4 (#6944), β-actin (#3700), Sox2
(#3579) were from Cell Signaling Technology (Danvers, MA). Inhibitors
dorsomorphin (#p5499), SB431542 hydrate (#S4317), LDN193189 (#SML0559)
were from Sigma-Aldrich. ML347 (#4945) was from Tocris Bioscience. Leptomycin
B (SC-358688) was from Santa Cruz. Cycloheximide (#97064-724) was
purchased from VWR. Actinomycin D (AAJ60148LB) was purchased from Fisher
Scientific. BMP2, BMP9, Activin and TGFβ1 were from R&D Systems.
Generation of transient knockdown cells using lentiviral shRNA or siRNA
and transfection of plasmid DNA
For transient SMAD1 knockdown, OVCAR3 cells were infected with SMAD1
shRNA lentivirus or Non-targeting control (NTC) construct (sequence in Table 4.1)
in the presence of 10µg/mL polybrene (hexadimethrinebromide). Lentiviral shRNA
plasmids were obtained from Dharmacon and are listed in Table 4.1. Plasmid
extraction was done using the Zymo® Miniprep kit (Zymo Research, Irvine, CA).
The lentiviral particles were generated at the COBRE Center for Targeted
Therapeutics Core Facility (University of South Carolina). For SMAD4 knockdown,
OVCAR3 cells were transfected with 10nM SMAD4 siRNA or universal negative
scramble control, purchased from OriGene Technologies (Rockville, MD).
Transfection was performed using Lipofectamine RNAimax reagent from
ThermoFisher Scientific (Waltham, MA). The knockdown was confirmed by qPCR
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(sequence in Table 4.2). Transient DNA transfections were carried out in PA1
using Lipofectamine 3000 from Life Technologies (Carlsbad, CA). 1kb Sox2
promoter-luciferase plasmid construct (pGL3-Sox2) was purchased from Addgene
- #101761 (Watertown, MA).
RNA isolation and Quantitative Polymerase Chain Reaction (qRT-PCR)
analysis
Total RNAs were extracted from cells using Trizol reagent (Invitrogen,
Carlsbad, CA) and chloroform. RNA was retro-transcribed using 5x iScript Reverse
Transcription Supermix (#1708840) and the Sso Advanced Universal SYBR Green
Supermix (Bio-Rad #1725271) from Bio-Rad (Hercules, CA). All expression data
were normalized to those for RPL13A. qPCR primer sequences are listed in Table
4.2.

Luciferase Assay
HEK293 Cells were transfected with the pGL3-Sox2 promoter reporter
plasmid for 24h. Treatment with BMP2 or BMP9 (10 nM) was added to the media
for 24 hours. Cells were collected and lysed in 1 × passive lysis buffer (Promega)
according to manufacturer’s instructions. To measure luciferase activity, 20 μL of
lysate was added to 25 μL of Luciferase Assay Reagent (Promega), and
luminescence was quantitated using a luminometer (Biotek).
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Immunofluorescence
Cells were fixed in 4% paraformaldehyde, permeabilized in 0.3% TX-100,
and blocked with 1% BSA PBS. Primary antibody (1:200) incubation for an hour
was followed by 30-minute incubation with Alexa Fluor 488 (H+L) (#A11008 Life
Technologies). After washing, cells were stained with 4′6-diamidino-2-phenylindole
(Roche). Imaging was performed using an Olympus IX81 motorized inverted
microscope.
Statistical analysis
All in vitro experiments were conducted at least three times and in triplicate
when applicable or as indicated in figure legends. In vitro experiments were
analyzed using parametric statistics (analysis of variance global test with
Bonferroni-corrected 2-tailed Student’s t-tests as post hoc tests) and presented as
mean ± SEM. In cases where data were normalized to control, one-sample
Student’s t-test was used with an expected value of 1 or 100% in order to decrease
the likelihood of a type I error. All statistical analyses were conducted with
GraphPad Prism Software.
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Table 4.1. qPCR Primers

1
2
3

RPL13A F human: AGA TGG CGG AGG TGC AG.
RPL13A R human: GGC CCA GCA GTA CCT GTT TA
Smad1 F human: AAT TCC GGG GGT ATT GGC AG.
Smad1 R human: AAG TAA CCC AGT CAG CAC CG
Sox2 F human: GCC GAG TGG AAC TTT TGT CG.
Sox2 R human: GGC AGC GTG TAC TTA TCC TCC T

Table 4.2. shRNA sequence
SMAD1
pooled
sequence

AGAGACTTCTTGGGTGGAA
GTGTGTTGGTGGATGGTTT
TCAAGAACCTGTTTAGTTT
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